Dorzagliatin for type 2 diabetes with kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an experimental diabetes pill (dorzagliatin) in people with type 2 diabetes and moderate to severe kidney problems. The goal is to see if it helps keep blood sugar levels stable and is safe for those with reduced kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have type 2 diabetes and moderate to severe kidney disease (not on dialysis).
- Your A1c (a blood sugar test) is between 7.0% and 9.0%.
- You have been on a stable diabetes treatment for at least 4 weeks, including insulin (but not certain combination products) and possibly other diabetes pills.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You have no history of severe heart failure, stroke, or heart attack in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill, dorzagliatin, to see how it affects insulin and blood sugar control in people with early type 2 diabetes or high blood sugar after a sugary drink. It may help improve blood sugar management.
This trial tests an experimental pill (a glucokinase activator) in adults with a specific genetic form of diabetes called GCK-MODY. The study aims to see if the pill can help control blood sugar without causing dangerously low sugar levels.
This study tests a drug called dorzagliatin to see if it can help control blood sugar in adults with cystic fibrosis who have pancreatic insufficiency and abnormal glucose tolerance.
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
Hear when a new Chronic Kidney Disease (Stages 3b-5) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.